Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.17 -0.29 (-0.16%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,551,199
Open 174.98
Bid (Size) 175.70 (2)
Ask (Size) 176.25 (5)
Prev. Close 176.46
Today's Range 173.53 - 176.72
52wk Range 142.66 - 207.32
Shares Outstanding N/A
Dividend Yield 3.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Check Out What Whales Are Doing With ABBV
Via Benzinga
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. 
Via Benzinga

Performance

YTD
+10.23%
+10.23%
1 Month
-12.12%
-12.12%
3 Month
-10.58%
-10.58%
6 Month
+6.49%
+6.49%
1 Year
+21.86%
+21.86%

More News

Read More
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
Via The Motley Fool
It’s Been A Tough Month For Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
Market Whales and Their Recent Bets on ABBV Options
Via Benzinga
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Via Benzinga
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Via The Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
Via The Motley Fool
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
Where Will AbbVie Be in 5 Years?
Via The Motley Fool
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
Via Talk Markets
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
Via Benzinga
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'
Via Benzinga
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
Via The Motley Fool
Abbvie Stock Price Analysis – A Post-Humira Dip, New Drug Hopes, And Election Buzz – Is Now The Time To Buy?
Via Talk Markets
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.